Abstract
BackgroundIntestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases. The present study is aiming to investigate the potential roles and mechanisms of how intestinal microflora mediates lipid-reduction efficacy of Rosuvastatin.MethodsTo investigate the correlation between the intestinal microflora and efficacy of Rosuvastatin, we analyzed the diversity of intestinal microflora using PCR-DGGE analysis and 16S rDNA sequencing approaches. Furthermore, we compared the blood lipid levels of rat models with dysbiosis of intestinal microflora and control rats upon the Rosuvastatin administration.ResultsThe diversity of the intestinal flora was obviously decreased upon the antibiotic treatment, this effect could be maintained for 2 weeks after establishment of the models. Importantly, the results from 16S rDNA sequencing demonstrated that the abundance of Lactobacillus and Bifidobacterium was remarkably diminished upon the antibiotic treatment in antibiotic+Rosuvastatin-treated group compared to that of Rosuvastatin-treated group and control group. Correspondently, the lipid-reduction efficacy of Rosuvastatin was significantly compromised. However, the diversity of the intestinal flora was recovered 4 weeks after the antibiotic treatment. Subsequently, the lipid-reduction efficacy of Rosuvastatin was also recovered to level of the control rats treated with Rosuvastatin alone.ConclusionIntestinal flora could play an essential role in mediating the lipid-reduction efficacy of Rosuvastatin.
Highlights
Intestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases
Images and the quantification results suggested that Ceftriaxone treatment significantly decreased the diversity of intestinal microflora in Antibiotic+Statin group compared to water treated control group (Fig. 1a, b), indicating that antibiotic treatment remarkably impaired the diversity of the intestinal microflora in rats, mimicking the dysbiosis of intestinal microflora
Dysbiosis of intestinal microflora affects the efficacy of Rosuvastatin To investigate whether the disruption of the intestinal microflora can influence the efficacy of Rosuvastatin on rats, we measured the blood level of TG, total cholesterol (TC), high-density lipoprotein cholesterol (HDLc), and low-density lipoprotein cholesterol (LDLc) at the 0, 2, and 4 weeks after administration of Rosuvastatin
Summary
Intestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases. The present study is aiming to investigate the potential roles and mechanisms of how intestinal microflora mediates lipid-reduction efficacy of Rosuvastatin. Hydroxymethyl glutaric acid reductase (HMGCR) is the rate-limiting enzyme in the cholesterol synthesis pathway and plays an important role in the synthesis of cholesterol [4]. Accumulating studies revealed that intestinal microflora plays essential roles in metabolic diseases [7]. Impairment of intestinal microflora can exacerbate the body lipid metabolism disorders, as the flora-secreted bile acids, Wang et al Lipids in Health and Disease (2018) 17:151 cholesterol, and mevalonate can inhibit the expression of HMGCR. We hypothesis that abnormal intestinal flora might be another important factor affect the efficacy of Statins on different patients
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call